Peptide library › Metabolic & weight
Insulin analogs
Also known as Insulin lispro, Insulin aspart, Insulin glargine, Insulin detemir, Insulin degludec, Humalog, NovoRapid, Lantus, Tresiba
Lab-modified versions of insulin that work faster or last longer, used to treat type 1 and type 2 diabetes.
What people use it for
- Type 1 diabetes
- Type 2 diabetes when other treatments aren't enough
- Diabetes in pregnancy (some products)
What Insulin analogs does in the body
Insulin is the peptide hormone that moves sugar from the blood into cells. Small changes to its structure change how quickly it's absorbed: rapid-acting types cover meals, and long-acting types give a steady background level.
Strength of evidence
Strong: decades of clinical trials and use. Essential medicines.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
- Prescribing information (DailyMed, US): Official US label
- Patient leaflets (emc, UK): Official UK product information
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Low blood sugar (hypoglycaemia), which can be dangerous
- Weight gain
- Injection-site changes (lumps) if the same spot is used repeatedly
- Low potassium (rare)
Who should avoid it or take extra care
- Anyone not prescribed it: insulin can cause dangerous low blood sugar
- During an episode of low blood sugar
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
FDA-approved since 1996, starting with insulin lispro, followed by glargine, aspart, detemir, degludec and others. Prescription only.
How it's taken
Route: Injection under the skin by pen, syringe or pump; some forms are inhaled
How long it lasts (half-life): Varies by type: rapid-acting work for 3 to 5 hours, long-acting for 24 hours or more
Storage
Unopened pens and vials in the fridge; the one in use can usually be kept at room temperature for about 4 weeks. Never freeze.
Latest research & news
- Efficacy and Safety of Biosimilar Insulin Aspart (Rapilin®) Versus Originator (NovoRapid®) in Type 1 Diabetes: A Multicenter, Retrospective Cohort Study
Research · Study · PubMed · Diabetes Ther · 21 Nov 2026 - Influence of Infusion Duration and Tubing Length on Insulin Lispro Stability in Subcutaneous Insulin Pump Delivery Systems
Research · Study · PubMed · J Diabetes Sci Technol · 20 Nov 2026 - Massive high-concentration long-acting insulin overdose with suicidal intent - a case report
Research · Case report · PubMed · Open Life Sci · 20 Nov 2026 - An Alternative Strategy for Albumin Binding in Therapeutics. Proof-of-Concept Synthesis of Metallacarborane-Insulin Conjugates
Research · Study · PubMed · Bioconjug Chem · 18 Nov 2026 - Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management
Clinical trial · Recruiting · Phase 4 · Updated · ClinicalTrials.gov · 18 Nov 2026
Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.
Keep track of Insulin analogs privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Insulin analogs in Fiala How to installMore in Metabolic & weight
- SemaglutideOnce-weekly GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
- TirzepatideOnce-weekly dual GIP and GLP-1 receptor agonist for type 2 diabetes and weight management.
- RetatrutideExperimental triple GIP / GLP-1 / glucagon receptor agonist being studied for obesity.
- AOD-9604Modified fragment of human growth hormone once developed as an anti-obesity drug.
- LiraglutideOnce-daily GLP-1 receptor agonist; the predecessor of semaglutide.
- CagrilintideLong-acting amylin analog being studied for weight loss, mainly combined with semaglutide.
- MazdutideOnce-weekly dual GLP-1 and glucagon receptor agonist for weight management.
- SurvodutideExperimental once-weekly dual glucagon and GLP-1 receptor agonist being studied for obesity and fatty liver disease.
- DulaglutideOnce-weekly GLP-1 receptor agonist approved for type 2 diabetes.
- ExenatideThe first GLP-1 receptor agonist, originally found in Gila monster venom, approved for type 2 diabetes.
- PramlintideSynthetic version of the hormone amylin, used with mealtime insulin in diabetes.
- SetmelanotideMC4R agonist approved for rare genetic causes of severe obesity.
- 5-Amino-1MQSmall molecule sold alongside peptides for fat loss; blocks the enzyme NNMT. Not a peptide, and untested in people.
- AlbiglutideOnce-weekly GLP-1 medicine for type 2 diabetes, discontinued for business reasons in 2018.
- AmycretinExperimental single molecule that acts on both GLP-1 and amylin receptors, tested as a weekly injection and a daily tablet for weight loss.
- EfpeglenatideLong-acting experimental GLP-1 medicine that cut heart and kidney events in people with type 2 diabetes in a large trial.
- LixisenatideOnce-daily GLP-1 medicine for type 2 diabetes, now mainly used in a combined pen with insulin glargine.
- PemvidutideExperimental weekly injection that acts on GLP-1 and glucagon receptors, studied for obesity and fatty liver disease.
- PetrelintideExperimental long-acting amylin analog given weekly for weight loss, aiming for fewer stomach side effects than GLP-1 drugs.
- GlucagonEmergency hormone that quickly raises blood sugar during a severe hypo; also used to relax the gut during scans.
- DasiglucagonStable, ready-to-use version of glucagon for treating severe low blood sugar in people with diabetes.